PLx Pharma (NASDAQ:PLXP) announced its quarterly earnings data on Friday. The biotechnology company reported ($0.39) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.39), MarketWatch Earnings reports. The firm had revenue of $0.22 million during the quarter. PLx Pharma had a negative net margin of 12.57% and a negative return on equity of 169.28%.
Shares of PLx Pharma stock traded down $0.04 during midday trading on Friday, hitting $3.85. The company had a trading volume of 1,360 shares, compared to its average volume of 4,015. The firm has a market capitalization of $32.32 million, a P/E ratio of -1.97 and a beta of 1.68. The company has a quick ratio of 9.15, a current ratio of 9.15 and a debt-to-equity ratio of 0.93. PLx Pharma has a 12-month low of $3.05 and a 12-month high of $7.60.
Separately, ValuEngine lowered shares of PLx Pharma from a “hold” rating to a “sell” rating in a research report on Wednesday, September 12th.
About PLx Pharma
PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing non-steroidal anti-inflammatory drugs (NSAIDs) and other analgesics. The company's lead product candidates are Aspertec 81 mg and 325 mg, which are novel formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.
Featured Article: Conference Calls and Individual Investors
Receive News & Ratings for PLx Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PLx Pharma and related companies with MarketBeat.com's FREE daily email newsletter.